Simply Wall St.
How Recent Zanzalintinib Developments Are Reframing The Story For Exelixis (EXEL)
📈
AI Sentiment
Highly Positive
8/10
- Home
- NTRA
NTRA
Natera Inc.
as of 02-13-2026 12:01pm EST
$208.21
+$0.37
+0.18%
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 32.9B | IPO Year: | 2015 |
| Target Price: | $253.79 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $256.36 | Next Earning Date: | 02-27-2026 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 33.95% | Revenue Growth (next year): | 16.72% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 106.1M | FCF Growth: | N/A |
AI-Powered NTRA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 77.64%
77.64%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Natera Inc. (NTRA)
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Feb 3, 2026
Avg Cost/Share
$230.77
Shares
1,639
Total Value
$378,228.75
Owned After
137,847
SEC Form 4
RABINOWITZ DANIEL
Sell
SEC. AND CHIEF LEGAL OFFICER
NTRA Feb 3, 2026
Avg Cost/Share
$230.77
Shares
1,334
Total Value
$307,844.51
Owned After
223,813
SEC Form 4
Fesko John
Sell
PRESIDENT, CHIEF BUS. OFFICER
NTRA Feb 3, 2026
Avg Cost/Share
$230.95
Shares
3,594
Total Value
$830,278.57
Owned After
178,081
Brophy Michael Burkes
Sell
CHIEF FINANCIAL OFFICER
NTRA Feb 3, 2026
Avg Cost/Share
$227.82
Shares
6,939
Total Value
$1,580,926.39
Owned After
52,120
Sheena Jonathan
Sell
Director, Other
NTRA Feb 3, 2026
Avg Cost/Share
$230.77
Shares
435
Total Value
$100,384.08
Owned After
263,161
SEC Form 4
Chapman Steven Leonard
Sell
CEO AND PRESIDENT
NTRA Feb 3, 2026
Avg Cost/Share
$230.77
Shares
4,725
Total Value
$1,090,378.80
Owned After
123,156
SEC Form 4
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Feb 2, 2026
Avg Cost/Share
$231.48
Shares
3,000
Total Value
$694,309.17
Owned After
137,847
Chapman Steven Leonard
Sell
CEO AND PRESIDENT
NTRA Feb 2, 2026
Avg Cost/Share
$231.63
Shares
85,299
Total Value
$19,680,040.13
Owned After
123,156
Brophy Michael Burkes
Sell
CHIEF FINANCIAL OFFICER
NTRA Jan 29, 2026
Avg Cost/Share
$230.43
Shares
1,867
Total Value
$430,155.64
Owned After
52,120
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
1,200
Total Value
$285,194.88
Owned After
137,847
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Feb 3, 2026 | Sell | $230.77 | 1,639 | $378,228.75 | 137,847 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Feb 3, 2026 | Sell | $230.77 | 1,334 | $307,844.51 | 223,813 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Feb 3, 2026 | Sell | $230.95 | 3,594 | $830,278.57 | 178,081 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Feb 3, 2026 | Sell | $227.82 | 6,939 | $1,580,926.39 | 52,120 | |
| Sheena Jonathan | NTRA | Director, Other | Feb 3, 2026 | Sell | $230.77 | 435 | $100,384.08 | 263,161 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Feb 3, 2026 | Sell | $230.77 | 4,725 | $1,090,378.80 | 123,156 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Feb 2, 2026 | Sell | $231.48 | 3,000 | $694,309.17 | 137,847 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Feb 2, 2026 | Sell | $231.63 | 85,299 | $19,680,040.13 | 123,156 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 29, 2026 | Sell | $230.43 | 1,867 | $430,155.64 | 52,120 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jan 28, 2026 | Sell | $237.66 | 1,200 | $285,194.88 | 137,847 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
📈
AI Sentiment
Highly Positive
8/10
Compare NTRA vs Leading Stocks
See how NTRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.